| INTRODUC TI ON
Chronic obstructive pulmonary disease (COPD), one of the common chronic inflammatory diseases, is characterized by airflow limitation with incomplete reversibility, which devotes to abnormal inflammatory responses to noxious particles or gases in the lung.
1 Most COPD patients are classified as stable COPD or acute exacerbations COPD (AECOPD) because the chronic and stable course of COPD could be aggravated during short periods due to viral and bacterial infection. 2 According to World Health Organization (WHO), COPD is a major contributor to global morbidity and mortality, affecting estimated 251 million population and causing nearly 3 million deaths worldwide each year, and there is a strikingly raised tendency in its incidence especially in developing countries probably due to increased smoking rates and air pollution. 3 Even though great improvements have been achieved in early diagnosis and disease management, COPD is still the fourth leading cause of death, and it is predicted to become the third one in 2030, suggesting that COPD is a huge challenge threatening the global health. 3 In addition, AECOPD results in significant morbidity and has been reported to be among the major causes of death worldwide. 4 Hence, exploring additional and convincing biomarkers are necessary for supervision of disease progress and improvement of treatments outcomes in COPD patients.
Long noncoding RNAs (lncRNAs), as non-protein-coding RNA transcripts longer than 200 nt, locate within intergenic stretches or overlapping antisense transcripts of protein-coding genes, which closely correlate with chromosome modification, transcriptional activation or mRNA degradation to not only participate in normal physiological cellular activities, but also contribute to pathological mechanism, disease progression as well as disease prognosis.
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LncRNA antisense noncoding RNA in the INK4 locus (ANRIL), antisense of the cyclin-dependent kinase inhibitor 2B (CDKN2B) gene on chromosome 9p21, has been reported to involve into the processes of development and progression of chronic inflammatory diseases and contributes to inflammatory responses via the interaction with several genes or pathways including promoting caspase recruitment domain family member (CARD) 8 to repress nuclear factor kappa (NF-κB) pathway in ischemic stroke, or decreasing proinflammatory factor TGF-β1 expression to inducing thyroid cancer cells invasion and metastasis. [9] [10] [11] [12] [13] [14] Although lncRNA ANRIL has been reported to be a potential regulator through directly or indirectly mediating inflammatory cytokines in some chronic inflammatory diseases (such as atherosclerosis or periodontitis), little is known about the role of lncRNA ANRIL in COPD. 15, 16 Considering that COPD is one of typical inflammatory diseases, particularly in acute exacerbations of COPD that presents with more serious inflammatory responses as well as advanced disease conditions, and lncRNA ANRIL is a potential regulator related to inflammatory disorder, we conducted this study and the purpose of this study was to assess the predictive value of lncRNA ANRIL for acute exacerbations of COPD and to evaluate its correlation with inflammatory cytokines as well as Global initiative for chronic obstructive lung disease (GOLD) stage in COPD patients. 
| ME THODS

| Participants
| Ethics
The Ethics Committee of Shanghai East Hospital approved the study protocol, and all participants or their family members provided written informed consents before enrollment.
| Date collection
Demographic and clinical data were collected from all participants including age, gender, body mass index (BMI), and lung function test results (forced expiratory volume in one-second (FEV 1 ), FEV 1 (% predicted), FEV 1 /forced vital capacity (FVC)). Moreover, GOLD stages of AECOPD and stable COPD patients were also evaluated by physicians.
| Sample collection
Peripheral blood samples of AECOPD patients (within 24 hours after admission) and stable COPD patients were collected in tubes containing anticoagulant (ethylenediaminetetraacetic acid, EDTA).
Separation of the plasma was performed within 2 hours by centrifugation at 1900 g for 10 minutes, followed by 10-minutes high-speed centrifugation at 16 000 g of blood samples. Then, the supernatant sera were obtained and stored at −80°C for further detection. In addition, peripheral blood samples of HCs were obtained from physical examinations, and the plasma was separated correspondingly.
| Real-time polymerase chain reaction
Total RNA was extracted from plasma using TRIzol Reagent (TaKaRa, Kusatsu, Japan) according to manufacturer's protocol and then converted to cDNA using the Universal cDNA Synthesis kit (Exiqon, Denmark). After that, quantitative RT-PCR (qRT-PCR) was carried out using SYBR Premix Ex Taq kit (Takara, China The bold values was considered significant.
TA B L E 1 Characteristics of participants
| Enzyme-linked immunosorbent assay
According to the manufacturer instructions, tumor necrosis factor-α 
| RE SULTS
| Baseline characteristics
As presented in Table 1 , no difference was found in age (P = 0.469), gender (P = 0.311), or BMI (P = 0.171) among AECOPD patients, stable COPD patients, and HCs, while FEV 1 (P < 0.001), FEV 1 (%) (P < 0.001),
and FEV 1 /FVC (P < 0.001) was decreased in AECOPD patients and stable COPD patients compared with HCs. For AECOPD patients and stable COPD patients, no difference in GOLD stage (P = 0.970) was observed, whereas inflammatory cytokines levels were all increased in AECOPD patients, including TNF-α, IL-1β, IL-6, IL-8, IL-17, and LTB-4 (All P < 0.001) compared with stable COPD patients. LncRNA ANRIL expression was lower in AECOPD patients compared with stable COPD patients (P < 0.001) and HCs (P < 0.001), while no difference was observed in lncRNA ANRIL expression between stable COPD patients and HCs (P = 0.214). 
| Expression
| Predictive
| Correlation of lncRNA ANRIL with inflammatory cytokines in AECOPD patients
For AECOPD patients, lncRNA ANRIL expression was negatively correlated with TNF-α (r = −0.340, P < 0.001) ( Figure 3A) , IL-1β (r = −0.208, P = 0.015) ( Figure 3B ), IL-8 (r = −0.225, P = 0.008) ( Figure 3D ), IL-17A (r = −0.267, P = 0.002) ( Figure 3E ), and LTB-4 (r = −0.246, P = 0.004) ( Figure 3F ). In addition, lncRNA ANRIL expression was numerically negatively associated with IL-6 (r = −0.158, P = 0.067) ( Figure 3C ), but without statistical significance.
| Correlation of lncRNA ANRIL with Inflammatory cytokines in stable COPD patients
For stable COPD patients, lncRNA ANRIL expression was negatively associated with TNF-α (r = −0.168, P = 0.049) ( Figure 4A ), 
| D ISCUSS I ON
In the current study, we observed that (a) lncRNA ANRIL expression was lower in AECOPD patients compared with stable COPD patients as well as HCs, and it could distinguish AECOPD patients from stable COPD patients and HCs, suggesting that it could predict acute exac- Even though some interesting results were found in this study, there were still some limitations. Firstly, the sample size was relatively small in this study (a total of 136 AECOPD patients and 138 stable COPD patients); this might result in poor statistic power.
Secondly, the underlying mechanism of lncRNA ANRIL in COPD was not investigated. Thirdly, all the patients were recruited from our hospital. Therefore, further study with more COPD patients from multicenter is greatly needed.
In conclusion, lncRNA ANRIL associates with lower acute exacerbation risk, decreased inflammatory cytokines, and mild GOLD stage in COPD patients. F I G U R E 5 LncRNA ANRIL negatively correlated with GOLD stage in AECOPD patients but not in stable COPD patients. LncRNA ANRIL expression was negatively associated with GOLD stage in AECOPD patients (A), whereas no correlation was found in stable COPD patients (B). The comparison was determined by Kruskal-Wallis H rank sum test. P < 0.05 was considered significant. LncRNA ANRIL, long noncoding RNAs antisense noncoding RNA in the INK4 locus; GOLD, global initiative for chronic obstructive lung disease; AECOPD: acute exacerbations of chronic obstructive pulmonary disease; COPD, chronic obstructive pulmonary disease
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